Alcidion Group Limited · ASX:ALC
Alcidion — Shareholder Meeting (October 2025)
33 slides from Alcidion's shareholder meeting presentation, Oct 16, 2025
Slide 1: 2025 Annual General Meeting Chair Address and Presentation
16 October 2025 Australian Securities Exchange 20 Bridge Street Sydney NSW 2000 2025 Annual General Meeting Chair Address and Presentation Melbourne, Australia – Alcidion Group Limited (ASX: ALC) (Alcidion or Company) advises in accordance with ASX Listing Rule 3.13.3, a copy of the address by Chair
Slide 2: Chair's Address
Chair’s Address Good afternoon shareholders, colleagues, and guests. As Chair of Alcidion I’m pleased to address you at our 2025 Annual General Meeting. This year marks an important milestone in Alcidion’s 25-year journey, one characterised by transformation, growth, and unwavering commitment to mod
Slide 3: Chair's Address (continued): FY26 outlook
As we move into FY26, Alcidion enters the year with $34 million already secured in contracted revenue for the year, a strong pipeline, and an expanding installed base. The recent expansion with North Cumbria Integrated Care Trust further validates our growth strategy: continuing organic growth in es
Slide 4: Annual General Meeting October 2025
Annual General Meeting 16 October 2025
Slide 5: Introduction
INTRODUCTION
Slide 6: Acknowledgement of Country
ACKNOWLEDGEMENT OF COUNTRY Alcidion acknowledges the Traditional Custodians of the land we live and work upon and pay our respects to Elders past and present. COMMERICAL IN CONFIDENCE
Slide 7: Alcidion Group Board
Alcidion Group Board Rebecca Wilson Kate Quirke Daniel Sharp Andrew Way William Smart Non-executive Chair Group Managing Director/ Non-executive Director Non-executive Director Non-executive Director Chief Executive Officer Experienced company director with 25+ years of digital health sector 25 year
Slide 8: Format of Meeting
Format of Meeting 01 02 Chair Address Annual General Meeting Presentation 03 04 Q&A / Voting Procedure Formal Business of the Overview Meeting 05 General Questions
Slide 9: Chair Address
01. Chair Address
Slide 10: Annual General Meeting Presentation
02. Annual General Meeting Presentation
Slide 11: FY25 Results and Growth Strategy CEO Presentation
FY25 Results and Growth Strategy CEO Presentation October 2025
Slide 12: Snapshot
Snapshot
Slide 13: Investment Highlights
Investment Highlights Entering FY26 with significant momentum following a record FY25 and an established growth strategy underpinned by multiple drivers Mission-critical health High quality, diversified and Attractive unit economics with Capital light business model informatics platform serving long
Slide 14: FY25 – Financial Highlights
FY25 – Financial Highlights Record year across all key financial metrics $40.8M $28.5M $73.8M $5.1M $5.8M FY25 revenue ARR1 (as at 30 Jun-25) FY25 new & renewal TCV Underlying EBITDA3 Operating Cashflow positive Up 10% on pcp1 Up 31% on 30 Jun-24 Up 109% on pcp Up $8.5M Vs. ($3.4m) Up $12.9M vs. ($7
Slide 15: Market Drivers
Market Drivers Modern clinician needs and improved patient outcomes driving the digitisation of outdated, legacy systems Transition to digital Operating efficiency Increasing demand Increasing industry and workflow for seamless clinical support & funding solutions Shift towards digital within the Sm
Slide 16: Patient Journey with Miya Precision
Patient Journey with Miya Precison A value proposition at every point of care 8. Miya Record 14. Miya Command • A single, longitudinal view of a patient’s healthcare • Real-time access to 1. Miya Emergency journey across providers consolidated data 7. Smartpage • Effective care collaboration • Visua
Slide 17: Medium Term Growth Strategy and Outlook
Medium Term Growth Strategy and Outlook
Slide 18: Growth Pillars Support a Global Platform
Growth Pillars Support a Global Platform Multi-focus approach combining growth within existing customers, expansion in existing territories and attractive new markets and geographies Organic Growth 1 Scale Existing Markets 2 Evolve Product Functionality 3 Expand into New Geographies & Adjacencies •
Slide 19: Scale in Existing Markets
Scale in Existing Markets Recent success in Australia highlights the material opportunity still existing in Australia which is complemented by larger UK opportunities Australia UK & NHS markets Patient Flow England › Reduce incidence of bed blockage with effective patient flow tools › In June 2025,
Slide 20: Evolve Product Functionality
Evolve Product Functionality Bringing generative AI to healthcare Advanced technologies have always been part of the Miya Precision platform. Generative AI enables us to bring these capabilities into the clinical user interface, eliminating repetitive tasks & streamlining the capture of Example Miya
Slide 21: Expand into New Geographies
Expand into New Geographies Priority targets selected based on highly attractive risk / reward profile with smaller investment required to gain market entry Canada Middle East (Saudi Arabia, UAE) Win and Build Entry via Pilot Partner Steps taken to date: Steps taken to date: › Contracted experienced
Slide 22: Market Adjacencies
Market Adjacencies Interoperability and flexibility of platform architecture enables Miya to address critical patient challenges outside of acute setting Aged Care Community Care (Home Care, NDIS) Reviewing ability to extend functionality of Miya Precision Similar to Aged Care, functionality of Miya
Slide 23: Outlook
Outlook Momentum continuing into FY26 underpinned by high contracted revenue coupled with maturing pipeline of expansion & new opportunities As of 30 June 2025, contracted & Targeting to be FY26 EBITDA positive Started market testing, partner renewal revenue to be recognised in and deliver positive
Slide 24: Q&A / Voting Procedure Overview
03. Q&A / Voting Procedure Overview
Slide 25: Formal Business of the Meeting
04. Formal Business of the Meeting
Slide 26: Financial Statements and Reports
Financial Statements and Reports To receive and consider the Company’s Financial Statements, Directors’ Report and Auditor’s Report for the financial year ended 30 June 2025. Further Information › Matthew Gepp, Chief Financial Officer of Alcidion Group Limited and Grant Martinella of William Buck, t
Slide 27: Resolution 1 – Adoption of Remuneration Report
Resolution 1 – Adoption of Remuneration Report To consider and, if thought fit, pass the following as an ordinary resolution: “That for the purpose of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report as contained in the
Slide 28: Resolution 2 – Election of Andrew Way as a Director
Resolution 2 – Election of Andrew Way as a Director To consider and, if thought fit, pass the following as an ordinary resolution: “That Andrew Way, who was appointed as an addition to the Board since the last Annual General Meeting of the Company and who retires pursuant to clause 20.4 of the Compa
Slide 29: Resolution 3 – Approval of 10% Placement Facility
Resolution 3 – Approval of 10% Placement Facility Item withdrawn as announced to the ASX on 14 October 2025.
Slide 30: Voting Closure and End of Formal Business
VOTING CLOSURE AND END OF FORMAL BUSINESS
Slide 31: General Questions
O05. General Questions
Slide 32: Thank You
THANK YOU FOR YOUR ATTENDANCE
Slide 33: @ ALCIDION
A @ ALCIDION